80053817 - MACULA 2021

Saturday, January 23, 2021, 7:30 AM - 5:00 PM, Online


Over the past several years, there is a growing body of medical evidence demonstrating a clear biologic rationale for targeting vascular endothelial growth factors in the treatment of the neovascular form of agerelated macular degeneration, diabetic retinopathy, and related diseases. Furthermore, there are new imaging and therapeutic approaches to vitreomacular interface abnormalities, intraocular tumors, posterior uveitis, hereditary retinal degenerations, as well as surgical diseases of the retina. These areas of investigation are relatively new, and most ophthalmologists are not aware of the myriad of new clinical trials relevant to these diseases. Thus, these subjects are areas of great interest both to ophthalmologists who treat these diseases and to those who refer these cases for further management. Presentations were chosen to emphasize new information and consensus on the use of these biologic agents to treat the neovascular and non-neovascular forms of age-related macular degeneration, vitreomacular interface abnormalities, diabetic retinopathy, intraocular tumors, and posterior uveitis. In addition, cases were chosen highlighting new information being reported by randomized clinical trials in these disease areas.

Click here to register for Atlantic Coast Retina Conference to be held via Zoom on January 22, 2021.

WHO SHOULD ATTEND
This activity is intended for ophthalmologists, optometrists, and ophthalmic allied health professionals.

FEES
Physicans/Nurses/NPs/PAs/Allied Health Professionals....................................$50
Residents*/Fellows*..............................................................................................................$25
*with verification of status

LATE FEE AND REFUND POLICY
A $25 late fee applies to registrations received after 5:00 p.m. ET on January 17, 2021. A handling fee of $25 will be deducted for cancellation. Refund requests must be received by fax or mail by January 17, 2021.

1. Recognize the role of anti-angiogenic treatments for eyes with choroidal neovascularization from age-related macular degeneration or diabetic retinopathy, including proliferative diabetic retinopathy and diabetic macular edema.
2. Evaluate recent clinical studies evaluating treatments for hereditary retinal degenerations.
3. Recognize the role of imaging in the management of vitreomacular interface abnormalities.
4. Review the current and emerging therapeutic approaches for surgical retinal diseases.
5. Summarize the evidence of surgical and medical treatments for intraocular tumors.
6. Detect which patients are appropriate for biologic treatments of posterior uveitis.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION
American Board of Ophthalmology (ABO)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Maintenance of Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit.

OTHER CREDITS
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

National Commission on Certification of Physician Assistants (NCCPA)
PAs may claim a maximum of 7 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Saturday, January 23, 2021